Rebamipide

Min.Order / FOB Price:Get Latest Price

1 Kilogram	Negotiable

1 Kilogram

Negotiable

Min.Order :1 Kilogram
Purity: 98%
Payment Terms : L/C,T/T

Keywords

Rebamipide supplier Rebamipide China Rebamipide 98%

Quick Details

Appearance:powder
Application:API
PackAge:7.5KG
ProductionCapacity:|Metric Ton|Day
Storage:Room temperature
Transportation:by air or by sea

Superiority:

we have 3 OEM factories, 2 R&D labs. Aily is striving to improve reseach and development, meet social and customers needs with a unifying strategic idea.

Details:

1. Introduction of Rebamipide

Rebamipide, with the cas register number of 90098-04-7, can be called (+-)-2-(4-Chlorobenzoylamino)-3-(2(1H)-quinolinon-4-yl)propionic acid, mucosta, proamipide. Rebamipide is a gastroprotective drug, it is a compound selected from over 500 amino acid analogs of 2(1H)-quinolinone tested for gastroprotective action and for efficacy to heal experimental gastric ulcers. This drug stimulates prostaglandin generation in gastric mucosa and improves not only the speed but also the quality of ulcer healing. In addition, it protects the gastric mucosa against acute injury caused by various noxious and ulcerogenic factors.

Specification

Items	Specification	Results
Appearance	White or almost white crystaline powder	Conform
Clarity of solution	Clear and colourless	Conform
Loss on drying	≤3.%	1.8%
Related substance	≤0.4%	0.13%
Residue on ignition	≤0.07%	0.05%
Heavy metals	≤10ppm	Conform
Assy	≥99.0%	99.6%

2. Basic Information of Rebamipide

Rebamipide, an amino acid derivative of 2(1H)-quinolinone, is used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. It has also been used for the treatment of Beh?et's disease. Some studies have shown effectiveness in presbyacusis (age-related hearing loss).

1) Properties
(1)Polar Surface Area: 95.5;
(2)Index of Refraction: 1.634 ;
(3)Molar Refractivity: 95.077 cm³;
(4)Molar Volume: 265.848 cm³;
(5) Polarizability: 37.692 10-24cm³;
(6)Surface Tension: 58.3219985961914 dyne/cm;
(7)Density: 1.395 g/cm³;
(8)Flash Point: 374.104 °C;
(9)Enthalpy of Vaporization: 106.903 kJ/mol;
(10)Boiling Point: 694.97 °C at 760 mmHg.

2) Toxicity

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD50	oral	> 2gm/kg (2000mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 362, 1989.
mouse	LD50	intramuscular	1353mg/kg (1353mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BLOOD: CHANGES IN SPLEEN	Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 362, 1989.
mouse	LD50	intravenous	572mg/kg (572mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD KIDNEY, URETER, AND BLADDER: OTHER CHANGES	Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 362, 1989.
mouse	LD50	subcutaneous	2637mg/kg (2637mg/kg)	LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION KIDNEY, URETER, AND BLADDER: OTHER CHANGES SKIN AND APPENDAGES (SKIN): HAIR: OTHER	Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 362, 1989.
mouse	LDLo	oral	> 5gm/kg (5000mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 362, 1989.
rabbit	LD50	oral	> 3gm/kg (3000mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 362, 1989.
rat	LD50	intravenous	700mg/kg (700mg/kg)	KIDNEY, URETER, AND BLADDER: OTHER CHANGES	Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 362, 1989.
rat	LDLo	intramuscular	1gm/kg (1000mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) KIDNEY, URETER, AND BLADDER: OTHER CHANGES	Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 362, 1989.
rat	LDLo	oral	5gm/kg (5000mg/kg)	BEHAVIORAL: FOOD INTAKE (ANIMAL)	Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 362, 1989.
rat	LDLo	subcutaneous	4gm/kg (4000mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OTHER CHANGES: OLFACTION BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 362, 1989.

3) Mechanisms of action and efficacy in mucosal protection and ulcer healing
Rebamipide, a gastroprotective drug, is a compound selected from over 500 amino acid analogs of 2(1H)-quinolinone tested for gastroprotective action and for efficacy to heal experimental gastric ulcers. This drug stimulates prostaglandin generation in gastric mucosa and improves not only the speed but also the quality of ulcer healing. In addition, it protects the gastric mucosa against acute injury caused by various noxious and ulcerogenic factors. Based on these experimental results, rebamipide had been subsequently tested in several clinical trials and approved in Japan for therapeutic use in patients with gastric ulcers and patients with acute gastritis. The main purpose of developing this type of drug was to improve the quality of ulcer healing, especially in that antisecretory drugs lack this advantage. In a preliminary clinical study, rebamipide improved the quality of gastric ulcer healing and reduced future ulcer recurrence. A number of basic research studies have been performed to clarify the mechanisms of rebamipide's action. These studies demonstrated unique properties of rebamipide and convincingly showed that it increases gastric mucus glycoprotein components, stimulates migration and proliferation of wounded epithelial cell monolayers, increases expression of epidermal growth factor and its receptor in normal and ulcerated gastric mucosa, and scavenges active oxygen radicals. The drug also attenuates the activity of neutrophils and the production of inflammatory cytokines stimulated by NSAIDs and/or H. pylori. Therefore, rebamipide can contribute to the management of patients who are taking NSAIDs or are infected with H. pylori. The inhibition of immunoinflammatory responses by rebamipide in H. pylori-infected patients may prevent development of gastritis, peptic ulcer disease, its recurrence, and possibly gastric cancer. Moreover, rebamipide may enhance eradication of H. pylori-infection using standard eradication therapy.

View All